Laverock Therapeutics is developing a unique gene silencing platform for the creation of programmable, allogeneic cell therapies. Laverock’s differentiated technology allows generation of iPSC-derived products with improved efficacy, safety and accessibility, solving many of the limitations with existing approaches.

Laverock technology facilitates cell therapies which are both programmable and adaptive – engineering novel functionality which responds to both intra- and extra- cellular environmental cues. These next-generation products are able to deliver directed, responsive activities ensuring preferable on- and off-target profiles.

Their cellular engineering capabilities are supported by their proprietary computational and screening platforms, allowing them to rapidly identify preferred genetic modifications and associated phenotypic outputs through in vitro models.